ABSTRACT
In recent years,tumor immunotherapy has attracted more attention because of its remarkable curative effect in patients with advanced cancer,but often accompanied by immune related adverse events.Understanding the immune related adverse reaction rate,possible mechanism and adverse reaction evaluation criteria and treatment principle of the immune checkpoint inhibitors such as Ipilimumab,Nivolumab and Pembrolizumab,has important significance for the treatment of malignant tumor.
ABSTRACT
Breast cancer stem cells (CSCs) are the main causes leading to the failure of treatment of breast cancer and play important roles in the progression of breast cancer and drug resistance, which are closely related to the therapeutic resistance of radiotherapy and chemotherapy, and endocrine therapy.The metastatic potential and therapeutic resistance of CSCs are associated with epithelial mesenchymal transition and Hedgehog, Wnt, interleukin-6/signal transduction and tanscriptional activation factor 3, transforming growth factor-β and other signaling pathways.While some of the targeted drugs targeting these signaling pathways are undergoing clinical transformation, which is expected to provide new approach for the clinical treatment of breast cancer.